|
发表于 2013-3-25 01:13 PM
|
显示全部楼层
投资人 发表于 2013-3-25 09:29 AM
QCOR 从技术分析层面看,显现出走出阴影的乐观。 但从公司价值层面看,她孕育着巨大的风险。她在5年前被 ...
好像不止一种产品,我反正不懂药,yahoo + google translation
==============
Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human enzymes. Its research focuses on human enzymes that transiently modify tissue under the skin to facilitate the delivery of injected drugs and fluids, or to alter abnormal tissue structures for clinical benefit. The company’s products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to increase the dispersion and absorption of other injected drugs; in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Ultrafast Insulin program, a Phase II clinical trial product for the treatment of type 1 and 2 diabetes mellitus; PEGPH20, a new molecular entity that is in Phase II clinical trial for the treatment of solid tumors; and HTI-501, a lysosomal proteinase, which is in Phase 1/2 clinical trial for the treatment of edematous fibrosclerotic panniculopathy. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.; Pfizer Inc.; Baxter Healthcare Corporation; ViroPharma Incorporated; and Intrexon Corporation for the development of three product candidates. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
=========
Halozyme Therapeutics公司是一家生物制药公司,从事的研究,开发和商业化,人类的酶。其研究侧重于人类的酶瞬时修改皮肤组织,以便利提供的注射药物和液体,或改变组织结构异常的临床效益。该公司?S产品,基于Enhanze技术,专利的重组人透明质酸酶,即允许的皮下给药的可注射的生物制剂,如单克隆抗体和其他治疗性分子,以及小分子和流体。它提供的配方rHuPH20 Hylenex重组,促进皮下积液管理,实现水化,增加分散和吸收其他注射药物,皮下尿路造影,和不透X线的吸收,提高代理商。一种新的分子实体,该公司还开发超快胰岛素方案,用于治疗1型和2型糖尿病患者的II期临床试验的产品; PEGPH20,在第二阶段的临床试验,用于治疗实体肿瘤,并HTI-501一种溶酶体蛋白酶,这是在1/2期临床试验,用于治疗水肿fibrosclerotic panniculopathy的。它的合作伙伴关系,与F霍夫曼 - 罗氏公司和罗氏公司,公司,辉瑞公司,百特医疗用品公司,Viropharma公司注册成立,并Intrexon公司发展的三个候选产品。 Halozyme Therapeutics公司成立于1998年,总部设在美国加利福尼亚州圣迭戈,。
============== |
|